Editorial: the coming revolution in the treatment of prostate cancer patients.
Daniel P
DP
Petrylak
Ronald
R
de Wit
D000726:Androgen Antagonists / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077143:Docetaxel; D004961:Estramustine / Q000008:administration & dosage; D005544:Forecasting; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids; D014747:Vinblastine / Q000008:administration & dosage
D000726:Androgen Antagonists; D043823:Taxoids; D000077143:Docetaxel; D004961:Estramustine; D014747:Vinblastine; D017239:Paclitaxel